Page 102 - medicina-integrativa_compress

CAPÍTULO 10 ANSIEDAD 93

BIBLIOGRAFÍA 24. Pittler M, Ernst E: Efficacy of kava extract for treating anxiety:
Systematic review and meta-analysis. J Clin Psychopharmacol
1. Pozuelo L, Ross J, Sussman N, et al: The anxiety spectrum: Which 20:84-89, 2000.
disorder is it? Patient Care 33:13, 1999. 25. Shulgin AT: The narcotic pepper: The chemistry and pharmacology
2. Goldberg RJ: Practical Guide to the Care of the Psychiatric Patient, of Piper methysticum and related species. Bull Narc 25:59-74,
2nd ed. St. Louis, CV Mosby, 1998. 1973.
3. American Psychiatric Association: Diagnostic and Statistical Manual 26. Lebot V, Merlin M, Lindstrom L: Kava: The Pacific Drug.
of Mental Disorders, Fourth Edition, Primary Care Version. New Haven, CT, Yale University Press, 1992.
Washington, DC, American Psychiatric Association, 1995. 27. Pepping J: Alternative therapies: Kava: Piper methysticum.
4. Kaplan HI, Sadoch BJ: Anxiety disorders. In Kaplan HI, Sadock BJ Am J Health Syst Pharm 56:957-960, 1999.
(eds): Kaplan and Sadock’s Synopsis of Psychiatry, 8th ed. 28. Almeida JC, Grimsley EW: Coma from the health food store:
Baltimore, Williams & Wilkins, 1998, pp 581-628. Interaction between kava and alprazolam. Ann Intern Med
5. Scheweitzer E: Generalized anxiety disorder: Longitudinal course 125:940-941, 1996.
and pharmacologic treatment. Psychiatr Clin North Am 18:843-857, 29. Schelosky L, Raffauf C, Jendroska K, Poewe W: Kava and
1995. dopamine antagonism. J Neurol Neurosurg Psychiatry 58:
6. Lydiard RB: Anxiety and the irritable bowel syndrome: Psychological, 639-640, 1995.
medical, or both? J Clin Psychiatry 58(Suppl 13):51-58, 1997. 30. Norton SA, Ruze P: Kava dermopathy. J Am Acad Dermatol
7. Stewart SH, Taylor S, Jang KL, et al: Causal modeling of relations 31:89-97, 1994.
among learning history, anxiety sensitivity, and panic attacks. 31. Shultz V, Hansel R, Tyler VE: Kava as an anxiolytic. In Rational
Behav Res Ther 39:443-456, 2001. Phytotherapy: A Physicians’ Guide to Herbal Medicine. Berlin,
8. Heim C, Ehlert U, Hellhammer DH: The potential role of Springer-Verlag, 1998, pp 65-73.
hypocortisolism in the pathophysiology of stress-related bodily 32. Brinker F, Stodart N: Herbal Contraindications and Drug
disorders. Psychoneuroendocrinology 25:1-35, 2000. Interactions, 2nd ed. Sandy, OR, Eclectic Medical Publications,
9. Osher Y, Hamer D, Benjamin J: Association and linkage of anxiety 1998.
related traits with a functional polymorphism of the serotonin 33. Blumenthal M: Kava safety questioned due to case reports of liver
transporter gene regulatory region in an Israeli sibling pair. Mol toxicity. HerbalGram 55:26-32, 2002; http://www.herbalgram.org/
Psychiatry 5:216-219, 2000. herbalgram/articleview.asp?a=2147
10. Paluska S, Schwenk TL: Physical activity and mental health: Current 34. Gruenwald J, Mueller C, Skrabal J: In-depth investigation into
concepts. Sports Med 29:167-180, 2000. EU market restrictions on kava products. Berlin: Phytopharm
11. Martinsen EW, Hoffart A, Solberg OY: Aerobic and non-aerobic Consulting, Report for Centre for Development of Enterprises.
forms of exercise in the treatment of anxiety disorders. Stress Med Brussels, March 2003.
5:115-120, 1989. 35. Dragull K, Yoshida WY, Tan CS: Piperidine alkaloids from
12. Moses J, Steptoe A, Mathews A, et al: The effects of exercise training Piper methysticum. Phytochemistry 6:193-198, 2003.
on mental well-being in the normal population: A controlled trial. 36. Clouatre DL: Kava kava: Examining new reports of toxicity.
J Psychosom Res 33:47-61, 1989. Toxicol Lett 150:85-96, 2004.
13. DiLorenzo TM, Bargman EP, Stucky-Ropp R, et al: Long-term 37. Gruenwald J: German Kava discussion re-opened [press release].
effects of aerobic exercise on psychological outcomes. Prev Med Berlin, International Kava Executive Council, May 24, 2005.
28:75-88, 1999. 38. Blumental M: American Botanical Council announces new safety
14. Dunn AL, Dishman RK: Exercise and the neurobiology of depression. information on Kava. ABC Safety Release, December 20, 2001.
Exercise Sport Sci Rev 19:41-98, 1991. 39. Youngken H: Textbook of Pharmacognosy, 6th ed. Philadelphia,
15. Bruce M, Lader M: Caffeine abstention in the management of Blakiston, 1948, pp 852-856.
anxiety disorders. Psychol Med 19:211-241, 1989. 40. Schellenberg R, Schwartz A, Schellenberg V, et al: Quantitative
16. Goodwin FK: Alcoholism research: Delivering on the promise. EEG-monitoring and psychometric evaluation of the therapeutic
Public Health Rep 103:569-574, 1989. efficacy of Biral N in psychosomatic diseases. Naturamed 4:9,
17. Maes M, Christophe A, Delanghe J, et al: Lowered omega-3 1994.
polyunsaturated fatty acids in serum phospholipids and cholesteryl 41. Panijel M: The treatment of moderate states of anxiety: Randomized
esters of depressed patients. Psychiatry Res 85:275-291, 1999. double-blind study comparing the clinical effectiveness of a
18. Bruinsma K, Taren DL: Dieting, essential fatty acid intake, and phytomedicine with diazepam. Therapiwoche 41:4659-4668,
depression. Nutr Rev 4:98-108, 2000. 1985.
19. McCarty MF: High-dose pyridoxine in “anti-stress strategy.” 42. Schultz V, Hansel R, Tyler VE: Rational Therapy: A Physicians’
Med Hypotheses 54:803-807, 2000. Guide to Herbal Medicine. Berlin, Springer-Verlag, 1998.
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
20. Murray M, Pizzorno J: Affective disorders. In Pizzorno JE, Murray 43. Reichert R: Valerian [clinical monograph]. Q Rev Nat Med Fall:
MT (eds): Textbook of Natural Medicine, 2nd ed. Philadelphia, 207-215, 1998.
Churchill Livingstone, 1999. 44. Schweitzer E, Rickels K: Strategies for treatment of generalized
21. Alpert JE, Mischoulon D, Nierenberg AA, Fava M: Nutrition anxiety disorder in the primary care setting. J Clin Psychiatry
and depression: The role of folate, methylation, and monoamine 58(Suppl 3):27-31, 1997.
metabolism in depression. J Neurol Neurosurg Psychiatry 45. Breier A, Albus M, Pickar D: Controllable and uncontrollable stress
16:228-232, 2000. in humans: Alterations in mood and neuroendocrine and
22. Zamorski M, Albucher R: What to do when SSRIs fail: Eight psychophysiological function. Am J Psychiatry 244:11, 1987.
strategies for optimizing treatment of panic disorder. Am Fam 46. Wang SM, Kain ZN: Auricular acupuncture: A potential treatment
Pract 8:1477-1484, 2002. for anxiety. Anesth Analg 92:548-553, 2001.
23. Blumenthal M, Busse WR, Goldberg A, et al: The Complete German 47. Romoli M, Giommi A: Ear acupuncture in psychosomatic medicine:
Commission E Monographs: Therapeutic Guide to Herbal The importance of Sanjiao (triple heater) area. Acupunct Electrother
Medicines. Austin, TX, American Botanical Council, 1998. Res 18:185-194, 1993.